

Jay W Hooper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4538060/publications.pdf>

Version: 2024-02-01

98
papers

6,356
citations

57631

44
h-index

74018

75
g-index

105
all docs

105
docs citations

105
times ranked

4694
citing authors

#	ARTICLE	IF	CITATIONS
1	A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge. <i>Journal of Virology</i> , 2022, 96, JVI0150421.	1.5	31
2	Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. <i>MBio</i> , 2022, 13, e0290621.	1.8	17
3	Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. <i>MAbs</i> , 2022, 14, 2002236.	2.6	14
4	A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge. <i>Npj Vaccines</i> , 2022, 7, 46.	2.9	9
5	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. <i>Vaccines</i> , 2022, 10, 717.	2.1	15
6	Exposure Route Influences Disease Severity in the COVID-19 Cynomolgus Macaque Model. <i>Viruses</i> , 2022, 14, 1013.	1.5	10
7	Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 847-858.	2.3	17
8	SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model. <i>Vaccines</i> , 2022, 10, 1104.	2.1	4
9	Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters. <i>Npj Vaccines</i> , 2021, 6, 16.	2.9	41
10	Development of a coronavirus disease 2019 nonhuman primate model using airborne exposure. <i>PLoS ONE</i> , 2021, 16, e0246366.	1.1	52
11	Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines. <i>Vaccine</i> , 2021, 39, 1101-1110.	1.7	8
12	Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection. <i>Cell Reports</i> , 2021, 35, 109086.	2.9	18
13	Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. <i>Journal of General Virology</i> , 2021, 102, .	1.3	6
14	Comparison of transcriptional responses between pathogenic and nonpathogenic hantavirus infections in Syrian hamsters using NanoString. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009592.	1.3	4
15	Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2020, 222, 572-582.	1.9	38
16	A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation. <i>Vaccines</i> , 2020, 8, 377.	2.1	19
17	Comparison of VSV Pseudovirus and Focus Reduction Neutralization Assays for Measurement of Anti-Andes orthohantavirus Neutralizing Antibodies in Patient Samples. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 444.	1.8	3
18	Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters. <i>Journal of Virology</i> , 2020, 94, .	1.5	58

#	ARTICLE	IF	CITATIONS
19	Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomal Bovines. <i>Scientific Reports</i> , 2020, 10, 8764.	1.6	32
20	Anti-HFRS Human IgG Produced in Transchromosomal Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models. <i>Frontiers in Microbiology</i> , 2020, 11, 832.	1.5	21
21	Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. <i>Transfusion</i> , 2020, 60, 1024-1031.	0.8	32
22	Particle-specific neutralizing activity of a monoclonal antibody targeting the poxvirus A33 protein reveals differences between cell associated and extracellular enveloped virions. <i>Virology</i> , 2020, 544, 42-54.	1.1	16
23	Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. <i>JCI Insight</i> , 2020, 5, .	2.3	186
24	Progress on the Prevention and Treatment of Hantavirus Disease. <i>Viruses</i> , 2019, 11, 610.	1.5	89
25	Three asymptomatic animal infection models of hemorrhagic fever with renal syndrome caused by hantaviruses. <i>PLoS ONE</i> , 2019, 14, e0216700.	1.1	14
26	Human Polyclonal Antibodies Produced from Transchromosomal Bovine Provides Prophylactic and Therapeutic Protections Against Zika Virus Infection in STAT2 KO Syrian Hamsters. <i>Viruses</i> , 2019, 11, 92.	1.5	7
27	Intranasal monkeypox marmoset model: Prophylactic antibody treatment provides benefit against severe monkeypox virus disease. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006581.	1.3	39
28	Fully Human Immunoglobulin G From Transchromosomal Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. <i>Journal of Infectious Diseases</i> , 2018, 218, S636-S648.	1.9	19
29	Innate immune responses elicited by Sin Nombre virus or type I IFN agonists protect hamsters from lethal Andes virus infections. <i>Journal of General Virology</i> , 2018, 99, 1359-1366.	1.3	5
30	A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. <i>PLoS ONE</i> , 2018, 13, e0192312.	1.1	64
31	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	13.9	314
32	Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. <i>Cmaj</i> , 2017, 189, E819-E827.	0.9	67
33	Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice. <i>Antiviral Research</i> , 2017, 146, 164-173.	1.9	22
34	An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection. <i>Scientific Reports</i> , 2017, 7, 4679.	1.6	21
35	Gastrointestinal Tract As Entry Route for Hantavirus Infection. <i>Frontiers in Microbiology</i> , 2017, 8, 1721.	1.5	35
36	Safety and immunogenicity of rVSV Δ G-ZEBOV-GP Ebola vaccine in adults and children in Lambaré, Gabon: A phase I randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002402.	3.9	57

#	ARTICLE	IF	CITATIONS
37	A lethal disease model for New World hantaviruses using immunosuppressed Syrian hamsters. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0006042.	1.3	13
38	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. <i>Scientific Reports</i> , 2016, 6, 24897.	1.6	35
39	Depletion of Alveolar Macrophages Does Not Prevent Hantavirus Disease Pathogenesis in Golden Syrian Hamsters. <i>Journal of Virology</i> , 2016, 90, 6200-6215.	1.5	11
40	Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever. <i>Journal of Virology</i> , 2016, 90, 3515-3529.	1.5	21
41	Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. <i>Vaccine</i> , 2016, 34, 1927-1935.	1.7	106
42	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. <i>New England Journal of Medicine</i> , 2016, 374, 1647-1660.	13.9	355
43	Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003803.	1.3	39
44	Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. <i>Journal of Infectious Diseases</i> , 2015, 212, S414-S424.	1.9	49
45	Cross-Protection Conferred by Filovirus Virus-Like Particles Containing Trimeric Hybrid Glycoprotein. <i>Viral Immunology</i> , 2015, 28, 62-70.	0.6	20
46	The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1156-1166.	4.6	251
47	Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1991-2004.	1.4	61
48	Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. <i>PLoS ONE</i> , 2015, 10, e0137786.	1.1	24
49	A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates. <i>Current Gene Therapy</i> , 2014, 14, 200-210.	0.9	64
50	A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation. <i>Clinical Microbiology and Infection</i> , 2014, 20, 110-117.	2.8	58
51	DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. <i>Science Translational Medicine</i> , 2014, 6, 264ra162.	5.8	59
52	A Lethal Disease Model for Hantavirus Pulmonary Syndrome in Immunosuppressed Syrian Hamsters Infected with Sin Nombre Virus. <i>Journal of Virology</i> , 2014, 88, 811-819.	1.5	46
53	DNA vaccines for HFRS: Laboratory and clinical studies. <i>Virus Research</i> , 2014, 187, 91-96.	1.1	27
54	A highly specific monoclonal antibody against monkeypox virus detects the heparin binding domain of A27. <i>Virology</i> , 2014, 464-465, 264-273.	1.1	42

#	ARTICLE	IF	CITATIONS
55	Construction and Nonclinical Testing of a Puumala Virus Synthetic M Gene-Based DNA Vaccine. <i>Vaccine Journal</i> , 2013, 20, 218-226.	3.2	37
56	A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). <i>Vaccine</i> , 2013, 31, 4314-4321.	1.7	57
57	Ribavirin Protects Syrian Hamsters against Lethal Hantavirus Pulmonary Syndrome After Intranasal Exposure to Andes Virus. <i>Viruses</i> , 2013, 5, 2704-2720.	1.5	35
58	The Syrian hamster model of hantavirus pulmonary syndrome. <i>Antiviral Research</i> , 2012, 95, 282-292.	1.9	61
59	A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. <i>Vaccine</i> , 2012, 30, 1951-1958.	1.7	58
60	Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies. <i>Virology</i> , 2012, 423, 134-142.	1.1	27
61	DNA Vaccine-Generated Duck Polyclonal Antibodies as a Postexposure Prophylactic to Prevent Hantavirus Pulmonary Syndrome (HPS). <i>PLoS ONE</i> , 2012, 7, e35996.	1.1	45
62	Side-by-Side Comparison of Gene-Based Smallpox Vaccine with MVA in Nonhuman Primates. <i>PLoS ONE</i> , 2012, 7, e42353.	1.1	36
63	Development and application of a flow cytometric potency assay for DNA vaccines. <i>Vaccine</i> , 2011, 29, 6728-6735.	1.7	12
64	Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease. <i>Virology Journal</i> , 2011, 8, 441.	1.4	23
65	The strategic use of novel smallpox vaccines in the post-eradication world. <i>Expert Review of Vaccines</i> , 2011, 10, 1021-1035.	2.0	18
66	T Cells Are Not Required for Pathogenesis in the Syrian Hamster Model of Hantavirus Pulmonary Syndrome. <i>Journal of Virology</i> , 2011, 85, 9929-9944.	1.5	76
67	Study of Andes virus entry and neutralization using a pseudovirion system. <i>Journal of Virological Methods</i> , 2010, 163, 416-423.	1.0	40
68	Evaluating the Orthopoxvirus Type I Interferon-Binding Molecule as a Vaccine Target in the Vaccinia Virus Intranasal Murine Challenge Model. <i>Vaccine Journal</i> , 2010, 17, 1656-1665.	3.2	8
69	<i>Hantavirus.</i> , 2009, , 379-411.		4
70	Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. <i>Vaccine</i> , 2009, 28, 494-511.	1.7	61
71	Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. <i>Virology</i> , 2008, 377, 19-29.	1.1	35
72	Treatment of hantavirus pulmonary syndrome. <i>Antiviral Research</i> , 2008, 78, 162-169.	1.9	123

#	ARTICLE	IF	CITATIONS
73	Mixing of M segment DNA vaccines to Hantaan virus and Puumala virus reduces their immunogenicity in hamsters. <i>Vaccine</i> , 2008, 26, 5177-5181.	1.7	29
74	Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. <i>Vaccine</i> , 2008, 26, 3507-3515.	1.7	32
75	Immune Serum Produced by DNA Vaccination Protects Hamsters against Lethal Respiratory Challenge with Andes Virus. <i>Journal of Virology</i> , 2008, 82, 1332-1338.	1.5	62
76	Hemorrhagic Fever with Renal Syndrome Caused by 2 Lineages of Dobrava Hantavirus, Russia1. <i>Emerging Infectious Diseases</i> , 2008, 14, 617-625.	2.0	99
77	Temporal Analysis of Andes Virus and Sin Nombre Virus Infections of Syrian Hamsters. <i>Journal of Virology</i> , 2007, 81, 7449-7462.	1.5	82
78	Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. <i>Vaccine</i> , 2007, 25, 1814-1823.	1.7	153
79	Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. <i>Virology</i> , 2007, 368, 331-341.	1.1	47
80	Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. <i>Vaccine</i> , 2006, 24, 4657-4666.	1.7	117
81	Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. <i>Virology</i> , 2006, 347, 208-216.	1.1	68
82	Human T-Cell Responses to Vaccinia Virus Envelope Proteins. <i>Journal of Virology</i> , 2006, 80, 10010-10020.	1.5	39
83	Subunit Recombinant Vaccine Protects against Monkeypox. <i>Journal of Immunology</i> , 2006, 177, 2552-2564.	0.4	139
84	Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. <i>Nature Medicine</i> , 2005, 11, 740-747.	15.2	346
85	Smallpox DNA Vaccine Protects Nonhuman Primates against Lethal Monkeypox. <i>Journal of Virology</i> , 2004, 78, 4433-4443.	1.5	267
86	Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters. <i>Virology</i> , 2004, 326, 130-139.	1.1	35
87	The M2 Gene Segment Is Involved in the Capacity of Reovirus Type 3 Abney to Induce the Oily Fur Syndrome in Neonatal Mice, a S1 Gene Segment-Associated Phenotype. <i>Virology</i> , 2003, 305, 25-30.	1.1	12
88	Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. <i>Virology</i> , 2003, 306, 181-195.	1.1	205
89	Rescue of hantaan virus minigenomes. <i>Virology</i> , 2003, 306, 219-224.	1.1	85
90	Active and Passive Vaccination against Hantavirus Pulmonary Syndrome with Andes Virus M Genome Segment-Based DNA Vaccine. <i>Journal of Virology</i> , 2003, 77, 9894-9905.	1.5	134

#	ARTICLE	IF	CITATIONS
91	Vaccines against hantaviruses. <i>Expert Review of Vaccines</i> , 2002, 1, 373-384.	2.0	45
92	A Lethal Disease Model for Hantavirus Pulmonary Syndrome. <i>Virology</i> , 2001, 289, 6-14.	1.1	229
93	DNA Vaccination with the Hantaan Virus M Gene Protects Hamsters against Three of Four HFPS Hantaviruses and Elicits a High-Titer Neutralizing Antibody Response in Rhesus Monkeys. <i>Journal of Virology</i> , 2001, 75, 8469-8477.	1.5	127
94	DNA Vaccination with Vaccinia Virus L1R and A33R Genes Protects Mice against a Lethal Poxvirus Challenge. <i>Virology</i> , 2000, 266, 329-339.	1.1	169
95	Comparison of the Protective Efficacy of Naked DNA, DNA-based Sindbis Replicon, and Packaged Sindbis Replicon Vectors Expressing Hantavirus Structural Genes in Hamsters. <i>Virology</i> , 1999, 263, 209-219.	1.1	77
96	DNA Vaccination with Hantavirus M Segment Elicits Neutralizing Antibodies and Protects against Seoul Virus Infection. <i>Virology</i> , 1999, 255, 269-278.	1.1	122
97	Role of the mu 1 protein in reovirus stability and capacity to cause chromium release from host cells. <i>Journal of Virology</i> , 1996, 70, 459-467.	1.5	71
98	Reovirus M2 gene is associated with chromium release from mouse L cells. <i>Journal of Virology</i> , 1993, 67, 5339-5345.	1.5	105